Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Erdafitinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
European Commission Approves BALVERSA for Metastatic Urothelial Carcinoma
Details : Balversa (erdafitinib) is a once-daily, oral FGFR kinase inhibitor approved for the treatment of adult patients with unresectable or metastatic urothelial carcinoma.
Product Name : Balversa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 23, 2024
Lead Product(s) : Erdafitinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cusatuzumab,Azacitidine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Argenx
Deal Size : Undisclosed
Deal Type : Termination
Details : The decision is based upon Janssen's review of all available cusatuzumab data and in consideration of the evolving standard of care for the treatment of acute myeloid leukemia.
Product Name : JNJ-74494550
Product Type : Antibody
Upfront Cash : Undisclosed
July 06, 2021
Lead Product(s) : Cusatuzumab,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Argenx
Deal Size : Undisclosed
Deal Type : Termination
Reset All
